1. Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma
- Author
-
Mahmoud Abu Hazeem, Osama Diab, Mitchell J. Kerfeld, Thamer Kassim, Adbullah Alsuwaidan, Dan Mcentire, Abdel Rahman Dajani, Jonathon Campbell, Ali H. Nayfeh, and Maryam Gbadamosi-Akindele
- Subjects
Prostate adenocarcinoma ,Oncology ,medicine.medical_specialty ,business.industry ,Case Report ,Stevens johnson ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,lcsh:RC254-282 ,Cancer treatment ,Clinical trial ,stomatognathic diseases ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Docetaxel ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,030211 gastroenterology & hepatology ,Single phase ,business ,medicine.drug - Abstract
Docetaxel is a commonly used chemotherapeutic agent in a variety of cancer treatment regimens. We present a case of apparent docetaxel-induced Stevens-Johnson syndrome (SJS) in a patient recently treated for metastatic prostate cancer. This medication is not classically associated with the development of SJS but in our case, along with a number of other case reports, and a single phase II clinical trial, an association was recognized. We encourage clinicians who employ the use of this medication to be aware of this relationship.
- Published
- 2019
- Full Text
- View/download PDF